Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 15, 2024 3:14pm
141 Views
Post# 36041768

RE:RE:RE:RE:As predicted. shorting away

RE:RE:RE:RE:As predicted. shorting awayI was asked why I suppport mangement?
First and formost, mangment of any company can not control the shareprice.
Next , they have recently aquired admitance to a world renowned Pancreatic cancer study.
Supported by many outside agancies.
The problem is that of time & failed events so far.
Like I said, many want instant results.
Pointing agai to the Mbc overall survival O.S.

That number is basd on real peoples lives that have been extended. Lengthing the outcome of a very long trial.
hard concept for some to grasp...the longer the MBc O.S. takes, the better.
Funny, mangement puts out promotional material & the FUDSTERS complain.
The same folks who claim there is no suppport from mangement for the company?
Biotechs are very risky, very , very risky.
One hand ? ONC has survived 20+ years. many have come & gone.
Dillution? I have yet to hear anyone come up with an alternative?
Thy need to keep the doors open & the trials going to get approval.
The recent CGAR endorcement is awsome news.
Stay tuned, the business side will follow.
ONC "mangement" knew full well the CGAR opportunity was arrivinig. Why sell out,, before fully matured.
My coments are certianly well above the head of most who are only lookng for blame
Yes thre is little  volume. 
Flying unde the radar.

soon to be discovered.


<< Previous
Bullboard Posts
Next >>